Efficacy News and Research

RSS
ODAC to review Cell Therapeutics' NDA for pixantrone

ODAC to review Cell Therapeutics' NDA for pixantrone

Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced

Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced

Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals

Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals

Individuals with lower educational status are associated with worse asthma symptoms

Individuals with lower educational status are associated with worse asthma symptoms

NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

Advanced Life Sciences Holdings' Restanza promising against tularemia

Advanced Life Sciences Holdings' Restanza promising against tularemia

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study

Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

ThromboGenics completes enrollment in second microplasmin Phase III trial

ThromboGenics completes enrollment in second microplasmin Phase III trial

Cellular Dynamics International launches iCell Cardiomyocytes

Cellular Dynamics International launches iCell Cardiomyocytes

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

Study suggests physical activity influences depression and fatigue by increasing self-efficacy

Italian patent issued for NPM1 to test patients with AML

Italian patent issued for NPM1 to test patients with AML

InSite Vision to advance new development candidate ISV-303

InSite Vision to advance new development candidate ISV-303

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Tarenflurbil drug does not appear to benefit Alzheimer’s patients

Tarenflurbil drug does not appear to benefit Alzheimer’s patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.